These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 10520836)

  • 1. Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers.
    Schillinger W; Hörnes N; Teucher N; Sossalla S; Sehrt D; Jung K; Hünlich M; Unsöld B; Geiling B; Ramadori G; Hilgers R; Schwörer H; Hasenfuss G
    Clin Res Cardiol; 2009 Jun; 98(6):391-9. PubMed ID: 19301059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
    Metz DC; Comer GM; Soffer E; Forsmark CE; Cryer B; Chey W; Pisegna JR
    Aliment Pharmacol Ther; 2006 Feb; 23(3):437-44. PubMed ID: 16423003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
    Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
    Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers.
    Hsu PI; Lo GH; Lo CC; Lin CK; Chan HH; Wu CJ; Shie CB; Tsai PM; Wu DC; Wang WM; Lai KH
    World J Gastroenterol; 2004 Dec; 10(24):3666-9. PubMed ID: 15534928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Treatment of Upper Gastrointestinal Bleeding.
    Oh DS; Pisegna JR
    Curr Treat Options Gastroenterol; 2003 Apr; 6(2):157-162. PubMed ID: 12628074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stress-related Mucosal Disease.
    Spirt MJ
    Curr Treat Options Gastroenterol; 2003 Apr; 6(2):135-145. PubMed ID: 12628072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrinoma.
    Li ML; Norton JA
    Curr Treat Options Oncol; 2001 Aug; 2(4):337-46. PubMed ID: 12057114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
    Metz DC; Ferron GM; Paul J; Turner MB; Soffer E; Pisegna JR; Bochenek WJ
    J Clin Pharmacol; 2002 May; 42(5):512-9. PubMed ID: 12017345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.
    Tang SJ; Nieto JM; Jensen DM; Ohning GV; Pisegna JR
    J Clin Gastroenterol; 2002 Jan; 34(1):62-3. PubMed ID: 11743248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching between intravenous and oral pantoprazole.
    Pisegna JR
    J Clin Gastroenterol; 2001 Jan; 32(1):27-32. PubMed ID: 11154164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC
    Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
    Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
    Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
    Metz DC
    Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
    Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
    Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.